How to Buy Sage Therapeutics (SAGE) Stock, Guide with Steps

sage therapeutics

Sage Therapeutics, Inc., a biopharmaceutical company, develops and markets drugs to treat disorders of the central nervous system. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company’s product portfolio also includes zuranolone, a neuroactive steroid, which is in phase III clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in a phase II clinical trial to treat essential tremor, and has also completed phase I clinical trial for epilepsy and Parkinson’s diseases. In addition, its product line includes SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan and South Korea; and a collaboration and licensing agreement with Biogen MA Inc. to jointly develop and commercialize the SAGE-217 and SAGE-324 products. The company was previously known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. schizophrenia and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan and South Korea; and a collaboration and licensing agreement with Biogen MA Inc. to jointly develop and commercialize the SAGE-217 and SAGE-324 products. The company was previously known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. schizophrenia and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize the SAGE-217 and SAGE-324 products. The company was previously known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. jointly develop and commercialize the SAGE-217 and SAGE-324 products. The company was previously known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. jointly develop and commercialize the SAGE-217 and SAGE-324 products. The company was previously known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc.

How to Buy Sage Therapeutics (SAGE) Stock, Guide with Steps

Do you want to learn how to buy Sage Therapeutics (SAGE) shares on Nasdaq safely and through a broker with official regulation? Does it call your attention to be able to make your profits profitable per month and extract interest in the stock market? Today I am going to show you how you can register an account with DEGIRO , a reliable German investment bank with minimal commissions, and how you will be able to obtain shares of the company Sage Therapeutics, Inc. (SAGE) (SAGE) quickly and intuitive.

The method is very intuitive :

  • First of all we are going to register in Degiro, an investment platform in which we are going to buy shares of the company Sage Therapeutics, Inc. (SAGE), (SAGE).
  • Then we will enter money and thus make our 1st investment.
  • Once we have the funds, we will proceed to locate the company Sage Therapeutics by its Ticker, in this case it is SAGE.
  • Finally, we will only add the number of shares we want to buy, the price at which we will buy them and the type of order.

The tutorial may have been a little short for you, so I’m going to show you the purchase process with screenshots.

How to open your account in Degiro.

As a first step we must register in degiro through the following link :

buy shares of Sage Therapeutics, Inc. (SAGE)

It will ask us for an email, a username and a password to access, and immediately we will have to continue with the link that they have sent us by email.

DEGIRO will shortly ask us for important information in order to accept our identity card . We will need to have on hand our passport, DNI (identity document) or driver’s license, our telephone number and the number of the bank account that we are going to apply to make our 1st deposit in IBAN format. If you do not perceive what this format is, you can check this simple guide article that we developed .

stock Sage Therapeutics

Once our account is verified, we will have to put money from the Enter / Withdraw section. We will be able to carry out a bank transaction that will take between 1 to 2 days, or carry out the deposit instantly using Sofort, a totally secure and 100% reliable payment gateway.

deposit money Sage Therapeutics

How to buy Sage Therapeutics (SAGE) shares through DEGIRO

When we finally have the money we have the possibility to buy our 1st share. You can select the place order button in the corner or use Degiro’s search engine and type in the ticker. In the next screenshot you will see that I have used the Amazon ticker but you should enter (SAGE), the Sage Therapeutics ticker. As it is an action, we will detect that the related businesses and companies are listed and there we will see to find Sage Therapeutics. The essential thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on NASDAQ (NDQ) and in your case Sage Therapeutics, Inc. (SAGE) is listed on Nasdaq. This step is very essential so do not make a mistake.

american bag calendar Sage Therapeutics

At the moment of developing the order we must pay special attention to what is next . We will have the possibility of placing a limit or market order. Imagine that you want to buy a share of Sage Therapeutics at 69.97, but its actual price is higher. With a limit order we will put the value at which we calculate to carry out the operation and until there are no shares for sale at that value, the purchase of the share will not be executed. With a market order, you will buy the number of shares that we have proposed at the actual selling price, which would be very close to the live listing price.

limit order broker Sage Therapeutics, Inc. (SAGE)

In both cases it is essential that you look at the order: permanent or of the day . For example, in Spain, the stock market is from morning until 1 in the afternoon, and in the US it coincides with the afternoon schedule in Spain. If an order is fixed, it will remain until it manages to be executed, but if you select the “of the day” option, when the day ends, if it is not executed, it will be removed from your file in Activity – Pending Orders.

I hope that this short text will be useful for you to invest in Sage Therapeutics. Thank you.

  Company information
  • Sage Therapeutics, Inc. (SAGE) Address: 215 First Street Cambridge, MA 02142 United States 617299 8380 Website: http://www.sagerx.com
  • Ticker: SAGE
  • Sector: Sanitary
  • Industry: Biotechnology
  • Number of employees: 298
  • Listed market: Nasdaq
  • Value last year: $69.97

company executives

Name Title Payment exercised Year of birth
Mrs. Kimi E. Iguchi CFO and Treasurer 536.37k 2.7 million 1962
Mr Michael Cloonan Director of operations 582.75 thousand 2.54 million 1972
Mrs Anne Marie Cook Sr. VP, General Counsel and Sec. 564.84k 2.14 million 1962
Dr. Jeffrey M. Jonas Director of Innovation, President of the Science and Technology Forum and Director 983.77k 29.44 million 1953
Dr. Stephen J. Kanes Medical director 580.67k 973.02k 1965
Mr. Barry E. Greene President, CEO and Director N/A N/A 1963
Dr. Heinrich Schlieker Ph.D. Senior Vice President of Technical Operations N/A N/A N/A
Dr. Albert J. Robichaud Scientific Director N/A N/A 1961
Mrs. Erin E. Lanciani Senior Vice President of People and Organizational Strategy N/A N/A 1969
Dr. Amy Schacterle Senior Vice President of Global Policy and Regulatory Affairs N/A N/A N/A

Recent Sage Therapeutics Events:

Recent Events June 10, 2020 Filed Complete 8-K: Submission of Matters to Securityholders’ Vote May 07, 2020 Filed Complete 8-K: Results of Operations and Financial Condition, Change of Directors or PriMay 07, 2020 Filed Complete 10-Q: Quarterly Report 07 Apr 2020 Filed Complete 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financing March 18, 2020 Filed Complete 8-K: Other Events, Financial Statements and Exhibits